Why ChromaDex Stock Is Sinking Today

why chromadex stock is sinking today

Sumary of Why ChromaDex Stock Is Sinking Today:

  • The initial decline stemmed from Tuesday’s decision by the U.S. District Court of Delaware to grant a summary judgment to Elysium Health, invalidating two of ChromaDex’s patents for vitamin B3 supplement Niagen.
  • It reported net sales of $15.4 million for its flagship product Tru Niagen in the second quarter, 87% of total revenue.
  • In addition, ChromaDex’s pipeline centers on nicotinamide riboside, the chemical name for Niagen.
  • The company has registered 49 clinical studies evaluating the drug.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.